title: Does the type of BCR/ABL junction predict the survival of patients with Ph1-positive chronic myeloid leukemia?
abstract: The prognostic value of the site of DNA rearrangement within the M-BCR on chromosome 22 or of the type of transcript has been debated in the last years. The majority of the studies do not support the hypothesis of a predictive value of such molecular parameters. Results coming from a multicentric, prospective trial, based on alpha-IFN therapy, seem to indicate a better karyotypic response in 3' rearranged patients. The possibility of evoking a cytotoxic immune response directed towards peptides originating from each of the different BCR/ABL junctions constitute an important challenge for the future.
authors.affiliation: Centro di Genetica e Citogenetica Oncologica, Istituto di Ematologia Lorenzo e Ariosto Seràgnoli, Università degli Studi, Bologna, Italia.
authors.forename: A
authors.initials: A
authors.lastname: Zaccaria
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: N
authors.initials: N
authors.lastname: Testoni
authors.forename: E
authors.initials: E
authors.lastname: Zuffa
authors.forename: P
authors.initials: P
authors.lastname: Farabegoli
authors.forename: D
authors.initials: D
authors.lastname: Russo
authors.forename: A
authors.initials: A
authors.lastname: Guerrasio
authors.forename: S
authors.initials: S
authors.lastname: Tura
mesh_terms: D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D016313:Genes, abl; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000453:epidemiology / Q000235:genetics*; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D016044:Fusion Proteins, bcr-abl